A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
This randomized phase II trial studies how well cabozantinib-s-malate, crizotinib,
volitinib, or sunitinib malate work in treating patients with kidney cancer that has spread
from where it started to nearby tissue or lymph nodes or to other places in the body.
Cabozantinib-s-malate, crizotinib, volitinib, and sunitinib malate may stop the growth of
tumour cells by blocking some of the enzymes needed for cell growth.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society